BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market open on Tuesday, February 3. InterMune will conduct a conference call and webcast, with accompanying slide presentation, to discuss results from the CAPACITY program at 8:00 a.m. EST (5:00 a.m. PST) on Tuesday, February 3.
To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 84164912. To access the live webcast of the conference call, with accompanying slides, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 84164912.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.
|SOURCE InterMune, Inc.|
Copyright©2009 PR Newswire.
All rights reserved